NCT02833974 - Effect of the GSK2245035 on the Allergen-induced Asthmatic Response | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

February 14, 2018

Study Completion Date

May 4, 2018

Conditions

Asthma

Interventions

DRUG

GSK2245035 Nasal Spray Solution

GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.

DRUG

Placebo Nasal Spray Solution

Nasal Spray Solution as for GSK2245035 without active ingredient.

Trial Locations (6)

22927

GSK Investigational Site, Großhansdorf

30625

GSK Investigational Site, Hanover

60596

GSK Investigational Site, Frankfurt am Main

65187

GSK Investigational Site, Wiesbaden

NW10 7EW

GSK Investigational Site, London

M23 9LT

GSK Investigational Site, Manchester